Latest Erbitux news
Addition of Cetuximab to CRT Cuts Locoregional Failure in Anal CA
by modernClinician Editorial Team
Addition of cetuximab to chemoradiation is associated with a reduction in locoregional failure rates in squamous cell carcinoma of the anal canal, according to a study published online Jan. 9 in the Journal of Clinical Oncology.
Cetuximab + Chemoradiation Can Cure HIV-Associated Anal Cancer
by modernClinician Editorial Team
Definitive chemoradiation can potentially cure HIV-associated squamous cell carcinoma of the anal canal, with the addition of cetuximab resulting in less locoregional failure, according to a study published online Dec. 12 in the Journal of Clinical Oncology.
Possible Benefit for Addition of Cetuximab to RT in Laryngeal CA
by modernClinician Editorial Team
For patients with hypopharyngeal or laryngeal carcinoma, the addition of cetuximab to radiotherapy is associated with a nonsignificant improvement in laryngeal preservation and laryngectomy-free survival, according to a study published online July 7 in JAMA Otolaryngology-Head & Neck Surgery.
Early Survivorship Care Linked to Improved Outcomes in Head, Neck Cancer 
ASTRO Issues Guidance for Use of Radiation Therapy in Bladder Cancer 
Recommendations Updated for Radiation Therapy in Pancreatic Cancer 
Thymic Radiation Linked to Worse Outcomes in Patients With NSCLC 
Gene Mutation Identified That Increases Lung Cancer Risk 
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL 
Aircrew Face Higher Odds of Radiation-Related Cancer Deaths 
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors Monthly Specialist Briefings
Stay Connected
